^
    2d
    ANCHOR: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=748, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin
    3d
    A Study on the Adherence of Patients with Nasopharyngeal Carcinoma to Oral Capecitabine Based on Digital Nudge (ChiCTR2500114952)
    P=N/A, N=140, Not yet recruiting, Chongqing University Cancer Hospital; Chongqing University Cancer Hospital
    New trial
    |
    capecitabine
    3d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced rectal cancer (ChiCTR2500114358)
    P=N/A, N=41, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    Asingle-arm,open-label,multi-centerclinicalstudyofthecombinationofetotilizumabandanti-angiogenicdrugsand/orchemotherapyassecond-linetreatmentforpatientswithmetastaticcolorectalcancer. (ChiCTR2500113997)
    P=N/A, N=30, Not yet recruiting, Qingdao Traditional Chinese Medicine Hospital; Qingdao Traditional Chinese Medicine Hospital
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin
    3d
    Safety Study of the Combination Regimen Based on HuA21 Monoclonal Antibody for the Treatment of Advanced HER2-overexpressing Solid Tumors (ChiCTR2500112039)
    P=N/A, N=90, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel
    3d
    A randomized controlled study of CICAPLAST BAUME B5+ in the treatment of Capecitabine- related skin Adverse Reaction in cancer patients (ChiCTR2500115475)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Nanjing Medical University; The First Affiliated Hospital of Nanjing Medical University
    New trial
    |
    capecitabine
    3d
    Optimization of immunotherapy strategies for locally advanced and metastatic gastric cancer under the guidance of CTCs and ctDNA (ChiCTR2500113727)
    P=N/A, N=200, Recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • docetaxel • Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    3d
    Clinical study on the safety and efficacy of sintilimab combined with chemotherapy in neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (ChiCTR2500114611)
    P4, N=38, Recruiting, The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
    New P4 trial
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    Individualized Adjuvant Treatment Decision for Locally Advanced Nasopharyngeal Carcinoma Guided by a Dynamic Therapeutic Response Prediction Model (RAIRI): A Multicenter Randomized Controlled Phase III Trial (ChiCTR2500112850)
    P3, N=651, Not yet recruiting, National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Clinical
    New P3 trial
    |
    capecitabine
    3d
    Phase II/III Trial of SYS6010 plus Enlonstobart Injection ± Chemotherapy in Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ChiCTR2500112440)
    P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • leucovorin calcium • Enshuxing (enlonstobart) • SYS6010
    3d
    Organ Preservation in Patients With Early-Stage (cT2-3a/bN0M0) Mismatch Repair Proficient Low Rectal Carcinoma Via Neoadjuvant Short-Course Radiotherapy Followed by Chemotherapy Combined With PD-1 Inhibitor :A Prospective, Multicenter, Single-Arm, Phase II Trial (ChiCTR2500113784)
    P2, N=33, Not yet recruiting, The Sixth Affiliated Hospital of Sun Yat-sen University; The Sixth Affiliated Hospital of Sun Yat-sen University
    New P2 trial
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    3d
    A randomized controlled study of preoperative short-course radiotherapy + chemotherapy and immunotherapy combined with intestinal flora intervention for locally advanced middle and low rectal cancer (ChiCTR2600117587)
    P2, N=216, Not yet recruiting, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University
    New P2 trial
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin